Generic Precedex Availability
Last updated on Apr 10, 2025.
Precedex is a brand name of dexmedetomidine, approved by the FDA in the following formulation(s):
PRECEDEX (dexmedetomidine hydrochloride - injectable;injection)
-
Manufacturer: HOSPIRA
Approval date: December 17, 1999
Strength(s): EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) [RLD] [AP] -
Manufacturer: HOSPIRA
Approval date: March 13, 2013
Strength(s): EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) [RLD] [AP], EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) [RLD] [AP] -
Manufacturer: HOSPIRA
Approval date: November 14, 2014
Strength(s): EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML) [RLD] [AP] -
Manufacturer: HOSPIRA
Approval date: January 31, 2020
Strength(s): EQ 1MG BASE/250ML (EQ 4MCG BASE/ML) [RLD]
Is there a generic version of Precedex available?
A generic version of Precedex has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Precedex and have been approved by the FDA:
dexmedetomidine hydrochloride injectable;injection
-
Manufacturer: ACCORD HLTHCARE
Approval date: February 9, 2016
Strength(s): EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) [AP] -
Manufacturer: ACTAVIS INC
Approval date: October 17, 2016
Strength(s): EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) [AP] -
Manufacturer: AMNEAL
Approval date: May 15, 2023
Strength(s): EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) [AP], EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) [AP] -
Manufacturer: AMNEAL PHARMS CO
Approval date: May 20, 2020
Strength(s): EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) [AP], EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) [AP] -
Manufacturer: BAXTER HLTHCARE CORP
Approval date: August 21, 2018
Strength(s): EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) [AP], EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) [AP] -
Manufacturer: ENDO OPERATIONS
Approval date: August 18, 2014
Strength(s): EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) [AP] -
Manufacturer: ENDO OPERATIONS
Approval date: September 15, 2020
Strength(s): EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) [AP], EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) [AP] -
Manufacturer: EUGIA PHARMA
Approval date: March 17, 2016
Strength(s): EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) [AP] -
Manufacturer: EUGIA PHARMA
Approval date: December 7, 2020
Strength(s): EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) [AP], EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) [AP] -
Manufacturer: FRESENIUS KABI USA
Approval date: September 18, 2015
Strength(s): EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) [AP] -
Manufacturer: FRESENIUS KABI USA
Approval date: November 29, 2018
Strength(s): EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML) [AP], EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) [AP], EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) [AP] -
Manufacturer: GLAND
Approval date: August 20, 2015
Strength(s): EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) [AP] -
Manufacturer: GLAND
Approval date: June 3, 2020
Strength(s): EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) [AP], EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) [AP] -
Manufacturer: HENGRUI PHARMA
Approval date: September 19, 2017
Strength(s): EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) [AP] -
Manufacturer: HENGRUI PHARMA
Approval date: June 12, 2020
Strength(s): EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML) [AP], EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) [AP], EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) [AP] -
Manufacturer: HIKMA
Approval date: April 26, 2017
Strength(s): EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) [AP] -
Manufacturer: HIKMA
Approval date: January 30, 2020
Strength(s): EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) [AP], EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) [AP] -
Manufacturer: MEITHEAL
Approval date: January 18, 2019
Strength(s): EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) [AP] -
Manufacturer: MILLA PHARMS
Approval date: June 7, 2023
Strength(s): EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) [AP], EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) [AP] -
Manufacturer: MYLAN INSTITUTIONAL
Approval date: August 18, 2014
Strength(s): EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) [AP] -
Manufacturer: MYLAN LABS LTD
Approval date: August 27, 2020
Strength(s): EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) [AP], EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) [AP] -
Manufacturer: RISING
Approval date: November 24, 2014
Strength(s): EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) [AP] -
Manufacturer: SANDOZ
Approval date: June 14, 2016
Strength(s): EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) [AP] -
Manufacturer: TAGI
Approval date: November 23, 2020
Strength(s): EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML) [AP], EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) [AP], EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) [AP] -
Manufacturer: TEVA PHARMS USA
Approval date: November 28, 2017
Strength(s): EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) [AP] -
Manufacturer: WILSHIRE PHARMS INC
Approval date: December 4, 2019
Strength(s): EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) [AP], EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) [AP] -
Manufacturer: ZYDUS PHARMS
Approval date: February 27, 2018
Strength(s): EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) [AP]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Precedex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Dexmedetomidine premix formulation
Patent 10,016,396
Issued: July 10, 2018
Inventor(s): Roychowdhury Priyanka & Cedergren Robert A.
Assignee(s): HOSPIRA, INC.The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation.
Patent expiration dates:
- January 4, 2032✓
- January 4, 2032
-
Dexmedetomidine premix formulation
Patent 8,242,158
Issued: August 14, 2012
Inventor(s): Roychowdhury Priyanka & Cedergren Robert A.
Assignee(s): Hospira, Inc.The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation.
Patent expiration dates:
- January 4, 2032✓
- January 4, 2032
-
Dexmedetomidine premix formulation
Patent 8242158*PED
Issued: August 14, 2012
Inventor(s): Roychowdhury Priyanka & Cedergren Robert A.
Assignee(s): Hospira, Inc.The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation.
Patent expiration dates:
- July 4, 2032✓
- July 4, 2032
-
Dexmedetomidine premix formulation
Patent 8,338,470
Issued: December 25, 2012
Inventor(s): Roychowdhury Priyanka & Cedergren Robert A.
Assignee(s): Hospira, Inc.The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation.
Patent expiration dates:
- January 4, 2032✓
- January 4, 2032
-
Dexmedetomidine premix formulation
Patent 8338470*PED
Issued: December 25, 2012
Inventor(s): Roychowdhury Priyanka & Cedergren Robert A.
Assignee(s): Hospira, Inc.The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation.
Patent expiration dates:
- July 4, 2032✓
- July 4, 2032
-
Methods of treatment using a dexmedetomidine premix formulation
Patent 8,455,527
Issued: June 4, 2013
Inventor(s): Roychowdhury Priyanka & Cedergren Robert A.
Assignee(s): Hospira, Inc.The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation.
Patent expiration dates:
- January 4, 2032✓
- January 4, 2032
-
Methods of treatment using a dexmedetomidine premix formulation
Patent 8455527*PED
Issued: June 4, 2013
Inventor(s): Roychowdhury Priyanka & Cedergren Robert A.
Assignee(s): Hospira, Inc.The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation.
Patent expiration dates:
- July 4, 2032✓
- July 4, 2032
-
Dexmedetomidine premix formulation
Patent 8,648,106
Issued: February 11, 2014
Inventor(s): Roychowdhury Priyanka & Cedergren Robert A.
Assignee(s): Hospira, Inc.The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation.
Patent expiration dates:
- January 4, 2032✓
- January 4, 2032
-
Dexmedetomidine premix formulation
Patent 8648106*PED
Issued: February 11, 2014
Inventor(s): Roychowdhury Priyanka & Cedergren Robert A.
Assignee(s): Hospira, Inc.The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation.
Patent expiration dates:
- July 4, 2032✓
- July 4, 2032
-
Dexmedetomidine premix formulation
Patent 9,320,712
Issued: April 26, 2016
Inventor(s): Roychowdhury Priyanka & Cedergren Robert A.
Assignee(s): HOSPIRA, INC.The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation.
Patent expiration dates:
- January 4, 2032✓
- January 4, 2032
-
Dexmedetomidine premix formulation
Patent 9320712*PED
Issued: April 26, 2016
Inventor(s): Roychowdhury Priyanka & Cedergren Robert A.
Assignee(s): HOSPIRA, INC.The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation.
Patent expiration dates:
- July 4, 2032✓
- July 4, 2032
-
Dexmedetomidine premix formulation
Patent 9,616,049
Issued: April 11, 2017
Inventor(s): Roychowdhury Priyanka & Cedergren Robert A.
Assignee(s): HOSPIRA, INC.The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation.
Patent expiration dates:
- January 4, 2032✓
- January 4, 2032
-
Dexmedetomidine premix formulation
Patent 9616049*PED
Issued: April 11, 2017
Inventor(s): Roychowdhury Priyanka & Cedergren Robert A.
Assignee(s): HOSPIRA, INC.The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation.
Patent expiration dates:
- July 4, 2032✓
- July 4, 2032
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- December 16, 2025 - NEW PATIENT POPULATION
More about Precedex (dexmedetomidine)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Latest FDA alerts (2)
- Side effects
- Dosage information
- During pregnancy
- Drug class: miscellaneous anxiolytics, sedatives and hypnotics
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
- Precedex prescribing information
- Precedex Concentrate (FDA)
- Dexmedetomidine Hydrochloride (AHFS Monograph)
Other brands
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
AP | Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions. It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.